Less than EPPIC data cast shadow over global prospects for Kureha/MTP's CKD therapy
This article was originally published in Scrip
Executive Summary
Japan's Kureha Corp and its development partner Mitsubishi Tanabe Pharma (MTP) have been working on a Phase III international clinical programme for an adsorbent therapy for chronic kidney disease (CKD) for more than three years.